EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End

Zinger Key Points
  • Aurora works with flower and extracts, but the CEO is excited about the opportunity in biosynthetics.
  • Aurora is still on track to hit its goal of becoming EBITDA-positive by the end of the year.

Miguel Martin, CEO of Aurora Cannabis Inc ACB, discussed growing Aurora into the leader of the international medical cannabis market at the Benzinga Cannabis Capital Conference on Wednesday.

International Markets: Martin said Aurora currently has a 23% market share in the Canadian medicinal cannabis business, where it enjoys margins of about 62% compared to margins in the low 30s for Canadian recreational cannabis sales.

"At least in the short-term the growth globally, at least from a profit standpoint, is all around medical cannabis," Martin said.

Aurora operates in 12 countries and holds number one or number two positions in many of those countries.

"I know we're all consumed with what's happening here in the U.S., and that's a big part, but I would encourage you to spend time on what's happening in Germany or Israel or France or the U.K. or even now the Netherlands, which is a $2.5 billion market that's equally the size of Canada," he said.

Martin said a big part of the challenge for Aurora and other medical cannabis producers is educating physicians on the benefits of cannabis and how best to prescribe it to patients.

"What we're really excited about is around the world you're seeing a real growth in clinical research around the efficacy for those clinicians and physicians that are looking for that type of hard science for their patients," he said.

Also Read: EXCLUSIVE: Why This Congressman Says Politicians Need Firsthand Look At Cannabis Industry

Biosynthetics: Right now, Aurora works with flower and extracts, but Martin said he is really excited about the opportunity in biosynthetics.

"We were able to purchase a company that has what we believe is some of the most cutting-edge biosynthetic IP assets both in the plant and outside of the plant," he said.

"Obviously the very famous Epidiolex drug we see, which is an isolate-based product in the U.S., lends itself to the isolation of those molecules having significant economics," Martin said.

Epidiolex was the first drug ever approved by the FDA in 2018 that is derived from marijuana. It's parent company G.W. Pharmaceuticals was acquired by Jazz Pharmaceuticals PLC JAZZ in 2021 for $7.2 billion.

"The minor cannabinoids, which we don't talk a lot about, whether it's CBG or CBN or CBA, the economics and the extraction of them right now is fairly prohibitive. Biosynthetics really opens up significant economics, both domestically and internationally, around those minor cannabinoids," Martin said.

Financial Outlook: From a business perspective, Martin says Aurora is still on track to hit its goal of becoming EBITDA-positive by the end of the year.

"I'm here to recommit to that EBITDA-positive by adding, by the end of our fiscal year, we're absolutely confident that we're going to be in good position to not only meet that but also be able to grow."

Learn more about this and other upcoming Benzinga Cannabis events at this link.

Posted In: Benzinga Cannabis Capital ConferenceCCCCCC22Miguel MartinCannabisNewsPenny StocksSmall CapEventsExclusivesMarketsInterview

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.